Bollard Group’s Castle Biosciences CSTL Stock Holding History

Bollard Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-139	Closed	-$2K	–	444
2023 Q2	$2K	Buy	+139	New	+$2.82K	﹤0.01%	515

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bollard Group's CSTL Position: Q3 2023 in Review

Bollard Group sold out of Castle Biosciences (CSTL) in Q3 2023, closing a stake of 139 shares — an estimated $2K sold.

Bollard Group first reported a position in CSTL in Q2 2023 and held it in 1 quarter. The position peaked at $2K in Q2 2023. 135 funds tracked by Wall St. Rank hold CSTL as of Q3 2023.

Bollard Group reported no remaining Castle Biosciences position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 139 Castle Biosciences shares in Q3 2023, an estimated $2K.
Bollard Group first reported a position in Castle Biosciences in Q2 2023 and held it in 1 quarter.
Bollard Group's Castle Biosciences position peaked at $2K in Q2 2023.
135 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.